News
Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback